Suto H, Okano K, Oshima M, Ando Y, et al. Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Pancreas 2022;51:269-277.
PMID: 35584385